SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -106.45 Billion KRW | 4.91% |
| 2022 | -111.95 Billion KRW | -1464.04% |
| 2021 | 8.2 Billion KRW | -91.54% |
| 2020 | 96.99 Billion KRW | -12.37% |
| 2019 | 110.69 Billion KRW | -17.07% |
| 2018 | 133.47 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -192.09 Billion KRW | -43.25% |
| 2024 Q1 | -134.09 Billion KRW | -25.97% |
| 2023 Q1 | -174.68 Billion KRW | -56.04% |
| 2023 FY | -106.45 Billion KRW | 4.91% |
| 2023 Q4 | -106.45 Billion KRW | 52.47% |
| 2023 Q3 | -223.95 Billion KRW | -3.05% |
| 2023 Q2 | -217.32 Billion KRW | -24.41% |
| 2022 Q3 | 39.92 Billion KRW | 87.45% |
| 2022 Q2 | 21.29 Billion KRW | 127.88% |
| 2022 Q1 | -76.38 Billion KRW | -1030.74% |
| 2022 FY | -111.95 Billion KRW | -1464.04% |
| 2022 Q4 | -111.95 Billion KRW | -380.43% |
| 2021 Q4 | 8.2 Billion KRW | -67.71% |
| 2021 Q2 | 51.06 Billion KRW | -23.7% |
| 2021 Q3 | 25.41 Billion KRW | -50.23% |
| 2021 FY | 8.2 Billion KRW | -91.54% |
| 2021 Q1 | 66.92 Billion KRW | -31.0% |
| 2020 Q2 | 117.26 Billion KRW | 1.3% |
| 2020 FY | 96.99 Billion KRW | -12.37% |
| 2020 Q4 | 96.99 Billion KRW | -12.61% |
| 2020 Q3 | 110.99 Billion KRW | -5.35% |
| 2020 Q1 | 115.76 Billion KRW | 4.58% |
| 2019 Q2 | 127.92 Billion KRW | 8.0% |
| 2019 FY | 110.69 Billion KRW | -17.07% |
| 2019 Q3 | 126.61 Billion KRW | -1.03% |
| 2019 Q4 | 110.69 Billion KRW | -12.57% |
| 2019 Q1 | 118.45 Billion KRW | -11.25% |
| 2018 Q4 | 133.47 Billion KRW | 146.04% |
| 2018 Q3 | 54.24 Billion KRW | 0.0% |
| 2018 FY | 133.47 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | -3368.361% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 109.628% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 115.787% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | -895.219% |
| Green Cross Corporation | 674.31 Billion KRW | 115.787% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | 1422.589% |
| Celltrion, Inc. | 1325.8 Billion KRW | 108.029% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 106.906% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | -72.672% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 17.966% |